Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists

A Uccellatore, S Genovese, I Dicembrini, E Mannucci… - Diabetes therapy, 2015 - Springer
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

GLP-1 receptor agonists: a review of head-to-head clinical studies

JM Trujillo, W Nuffer, SL Ellis - Therapeutic advances in …, 2015 - journals.sagepub.com
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists

CF Shaefer Jr, P Kushner, R Aguilar - Postgraduate Medicine, 2015 - Taylor & Francis
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable
glucose-lowering medications approved for the treatment of adult patients with type 2 …

A plethora of GLP-1 agonists: decisions about what to use and when

SL Samson, AJ Garber - Current diabetes reports, 2016 - Springer
Incretin-based therapies are important addition to our armamentarium for the treatment of
type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP …

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

S Madsbad - Diabetes, Obesity and Metabolism, 2016 - Wiley Online Library
Currently, six glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are approved for
treating type 2 diabetes. These fall into two classes based on their receptor activation: short …

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

KB Harris, DJ McCarty - Therapeutic Advances in …, 2015 - journals.sagepub.com
Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

GLP-1 receptor agonists: an updated review of head-to-head clinical studies

JM Trujillo, W Nuffer, BA Smith - Therapeutic advances in …, 2021 - journals.sagepub.com
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

[HTML][HTML] A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

L Prasad-Reddy, D Isaacs - Drugs in context, 2015 - ncbi.nlm.nih.gov
The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …

[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art

MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

E Montanya - Expert opinion on pharmacotherapy, 2012 - Taylor & Francis
Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are a valuable addition to
the type 2 diabetes armamentarium. They increase insulin secretion and reduce glucagon …